Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06046729 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06046729 · ClinicalTrials.gov record · last posted 2026-08-21

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Name: A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa — clinical trial record (NCT06046729)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusCompleted

PhasePhase 2

SponsorEli Lilly and Company

Started2023-10-23

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.

Protocol amendment history 1 change detected by DataLookout

2026-08-22

Trial completed

Trial Details

NCT Number	NCT06046729
Lead Sponsor	Eli Lilly and Company
Conditions	Hidradenitis Suppurativa
Enrollment	352 participants
Start Date	2023-10-23
Primary Completion	2025-09-30 (estimated)
Study Completion	2026-08-17 (estimated)
Updated on ClinicalTrials.gov	2026-08-21